First-Line Afatinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation -Multicenter study on the Pharmacokinetics and pharmacogenetics of Afatinib
Phase 2
- Conditions
- patients aged 75 or older with advanced non small cell lung cancer harboring EGFR mutation
- Registration Number
- JPRN-UMIN000017050
- Lead Sponsor
- Hokkaido University Hospital, First department of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1)Concomitant treatment with other anticancer agent, radiotherapy, or immunotherapy. 2)Preexisting interstitial lung disease of chest CT 3)HBs antigen positive 4)HBs or HBc antibody positive, and HBV-DNA positive 5)EGFR minor mutation or exon 20 T790M 6)Active double cancer 7)Digestive disease influencing absorption of afatinib 8)Oral feeding difficulty 9)Patients whose attending doctor consider as inappropriate for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method